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CO-TRANSPLANTATION OF HLA-MATCHED RELATED DONORS CULTURE-
EXPANDED MESENCHYMAL STROMAL CELLS AND HEMATOPOIETIC
STEM CELLS IN THALASSEMIA MAJOR PATIENTS
Ghavamzadeh, A., Alimoghaddam, K., Hamidieh, A.A., Karimi, A.,
Bashtar, M., Shamshiri, A.R. Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
Objective:Use of mesenchymal stromal cells (MSCs) in hematopoi-
etic stem cell transplantation (HSCT), either for enhancement of he-
matopoietic engraftment or for prevention of graft versus host
disease (GVHD) is currently unknown. Following a positive phase
II study in all classes of thalassemia major, in this study we aimed
to show that co-transplantation of MSC and hematopoietic stem
cells (HSCs) from HLA-matched related donors after conditioning
regimen is safe and could facilitate engraftment and decrease
GVHD.
Methods: Between November 2006 and October 2009, 48 class
III thalassemia major patients were enrolled. In this double-blind
randomized clinical trial, HLA-identical related donors HSC
were transplanted (non-MSCs group, n5 23 with median age
of 16yrs and F/M5 11/12) or co-transplanted with MSCs
(MSCs group, n5 25 with median age of 17yrs and F/M5 8/
17) in thalassemia major patients. Patients received Cyclophos-
phamide-based or Fludarabine-based conditioning regimens and
short course methotrexate and cyclosporine as GVHD prophy-
laxis. On day 0, MSCs group patients were given MSCs intrave-
nously 4 hours before infusion of either bone marrow or
peripheral blood stem cells. The number of MSCs infused was
1.45-1.8010^6/kg.
Results: MSCs infusions were well tolerated. The median time to
neutrophil engraftment (absolute neutrophil count .0.510^9/L)
was 14 days for MSCs group and 13 days for non-MSCs group (p-
value5 0.16). The median time to platelet engraftment (platelet
count .2010^9/L) was 16 and 15 days, respectively (p-val-
ue5 0.34). Acute GVHD grade III-IV was observed respectively,
in 6(24%) and 4(17.5%). (p-value5 0.73). Median follow-up dura-
tion for alive patients was 10 months (ranged 1-28).
Conclusion: In this study we demonstrated that co-transplantation
of HLA-matched related donors MSCs with HSCs is seems to be
safe. We didn’t find statistical significant difference in acute
GVHD incidence, rate of non-engraftment, mortality rate and me-
dian time to neutrophil and platelet recovery between two groups.
Most probably explanations are small number of patients in study
groups and short follow-up period.151
STROMAL ELEMENTS AND ENGRAFTMENT IN AUTOLOGOUS HEMATO-
POIETIC PROGENITOR CELL (HPC) TRANSPLANT FOR MYELOMA
Veeraputhiran,M.1, Singh, Z.1, Barlogie, B.2, Cottler-Fox,M.1 1Univer-
sity of Arkansas for Medical Sciences, Little Rock, AR; 2Myeloma Institute
for Research & Therapy, Little Rock, AR
Introduction: Homing of HPC after transplant may be related to
stromal elements of the hematopoetic stem cell niche. We present
a retrospective analysis of bone marrow (BM) biopsies from patients
with myeloma prior to autologous HPC transplant and correlate
stromal variables with engraftment.
Material andMethods: 25 consecutive patients who underwent au-
tologous HPC transplant and survived 100 days post-transplant were
identified. BM biopsies done just prior to transplant were analyzed
using hematoxylin and eosin stained sections to evaluate the follow-
ing histological parameters: stromal components (fat, regenerating
adipocytes, fat necrosis, stromal edema, vasculature and stromal
hemorrhage); bone remodeling (osteoblasts vs osteoclasts); hemato-
poeisis (endosteal vs peri-sinusoidal hematopoesis); cellularity; and
interstitial fibrosis. Disease specific parameters including duration
of disease before transplant, conditioning therapy for transplant,
and total viable CD34 stem cells infused for transplant were also
identified. Time to platelet engraftment of 20,000/cmm and
50,000/cmm and time to WBC engraftment (ANC $500/cmm)
were determined. Univariate and multivariate regression analysis
were applied to determine, in a step-wise fashion, the correlationof independently significant BM stromal parameters with engraft-
ment.
Results: The median time to platelet engraftment of 20,000/cmm
and 50,000/cmm were 12 and 16 days respectively. The median
time to WBC engraftment was 11 days. Sinusoidal hematopoesis
was significantly correlated with delayed platelet engraftment to
20,000 ($ 12 days) (p5 0.034). Stromal edema correlated with de-
layed WBC engraftment ($ 11 days) (p5 0.042). No other variables
examined were statistically significant.
Conclusion: Pretransplant BM biopsy evaluation for stromal in-
jury as demonstrated by stromal edema and peri-sinusoidal hema-
topoiesis may be useful markers for predicting delayed platelet
and WBC engraftment in patients undergoing HPC transplant
for myeloma.152
MESENCHYMAL STEM CELLS: HEALTHY AT ANY AGE
Lund, T.C., Kobs, A., Blazar, B.R., Tolar, J. University of Minnesota,
Minneapolis, MN
Mesenchymal Stem Cells (MSC) are gaining in popularity as
an experimental therapy for a number of conditions including
graft-versus-host disease, Crohn’s disease, myocardial infarction,
etc. Most applications require that MSCs be expanded to achieve
an adequate cell-dose for therapy. Prior data suggest that MSC
undergo aging in culture and that MSC from older donors un-
dergo earlier senescence than MSC from younger donors. We
have observed over 100 MSC expansion cultures and it seemed
that early in the expansion period MSC from any age donor mi-
croscopically appeared healthy and showed no difference upon
differentiation into adipogenic, osteogenic, or cartilage lineages.
We hypothesized that MSC from any age donor would have sim-
ilar cellular fitness when expanded under incubation conditions
and limited passage to mimic cell handling that would be used
in a clinical preparation. We have compared the expression of
several markers of aging in MSCs obtained from a subset of
120 donors over a wide range of ages (8 months to 60 years).
We find that although MSC from older individuals produced
slightly fewer cells over a fixed number of passages and have
a slightly longer doubling time (54 hrs vs 42 hrs), a satisfactory
clinical product can still be obtained (multiple doses at .106
cell/kg). When MSC from young (0.8-6 years) and old (43-60
years) were compared there was no difference in cell surface
markers, lipofuscin, migration ability, or expression of aging
markers such as iNOS, PGE2, p16, and SOD. SOD activity
(0.025 vs 0.028 U/ml) and oxidative challenge death rate to hy-
drogen peroxide were not significantly different (1% vs 1.5%,
p5 0.14). Morphology by light microscopy and extent of qualita-
tive differentiation into osteogenic, adipogenic, and cartilage cell
types were also similar in old and young donor derived MSC. Fi-
nally, telomeres did not show a significant difference in length
between young and old donor-derived MSC early in passage.
We conclude that age may not need to be considered when de-
termining a potential MSC donor especially in light of the fact
that many clinical applications require only a limited culture
time (19-21 days) to achieve a sufficient number of cells for a use-
ful clinical product.153
AFRICAN AMERICAN ADULT DONORS RESPOND TO G-CSF WITH PRO-
GENITOR CELL YIELDS COMPARABLE TO CAUCASIAN AND HISPANIC DO-
NORS
Carilli, A.R.1, Sugrue, M.W.1, Chang, M.1, Fisk, D.2, Medei, M.2,
Williams, K.2, Wiggins, L.2, Wingard, J.R.1 1University of Florida,
Gainesville, FL; 2Shands Hospital at the University of Florida, Gaines-
ville, FL
Background: Because African Americans (AAs) have lower leuko-
cyte counts and cord bloods from AA neonates have fewer progenitor
cells, we examined the responses to G-CSF and progenitor cell yields
in healthy adult AAs.
Poster Session I S215Methods: We conducted a retrospective case control study. Blood
counts and progenitor cell yields from AA (N5 22) and Hispanic
(N5 12) normal donors were compared with Caucasian normal do-
nors (N5 34). Donor factors known to affect progenitor cell yields
were matched between groups for age, sex and weight. Donors gen-
erally received G-CSF (10mcg/kg daily) for 5 days. Twenty liter
aphereses were performed beginning on day 5.
Results: Counts from peripheral blood and aphereses products are
presented in the table.
Conclusion: These data suggest that despite lower baseline leuko-
cyte and neutrophil counts that responses to G-CSF and progenitor
cell yields after G-CSF in healthy AA donors are at least as good as
Caucasian and Hispanic donors.
AfricanParameter (mean/median) American Hispanic Caucasian p-value*Donor characteristicsAge 42/44 41.4/41 43.4/44 0.70Gender 8 M/14F 6 M/6F 14 M/20FWeight 89.2/86.1 77.5/77.2 80.9/81.5 0.23Baseline Blood CountsWBC count x10^3/uL 6.1/5.9 7.3/7.2 7.1/7.15 0.03Neutrophil count x 10^3/
uL3.4/3.2 4.4/4.5 4.5/4.5 .002Platelet count 10^3/uL 283/272 286/292 282.5/269 0.95Blood Counts after G-CSF,
before apheresisWBC count x10^3/uL 47.2/47.1 43.1/45.4 49/47.2 0.61Neutrophil count x10^3/
uL32.4/29.4 28.1/26 34.7/33.7 0.26Platelet count x10^3/uL 255/245 239/237 265.8/240.5 0.62% change of WBC count 792/703 619/595 704/682 0.47Product CountsTotal Nucleated Cell
Count x10^1010.2/9.72 9/8.76 9/8.9 0.24Total CD34 Count x10^8 9.5/7.33 7/5.49 6.4/5.7 0.10%CD34 of TNC 0.9/0.86 0.8/0.81 0.7/0.72 0.11CD34 Count/Kg of
donor weight x 10^610.7/9.1 9.2/7.3 8/7.3 0.16CD34 Count/L of blood
processed x 10^647.8/38.2 36.5/31.5 32/28.7 0.08* P-Values were obtained from the comparison between African Amer-
ican donors and Caucasian donors by two sided t-testHISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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INTRAVENOUS BUSULFAN/FLUDARABINE-BASED CONDITIONING REGI-
MEN IS A FEASIBLE AND EFFECTIVE OPTION IN UNRELATED CORD
BLOOD TRANSPLANTATION
Yamamoto, H.1, Uchida, N.1, Ishiwata, K.1, Nakano, N.1, Tsuji, M.1,
Araoka, H.2, Mori-Asano, Y.1, Wake, A.1, Yoneyama, A.2,
Makino, S.3, Taniguchi, S.1 1Toranomon Hospital, Tokyo, Japan; 2Tor-
anomon Hospital, Tokyo, Japan; 3Toranomon Hospital, Tokyo, Japan
Intravenous busulfan and fludarabine (ivBu + Flu) has been
widely used as preparative regimen in the setting of bone marrow
or peripheral blood stem cell transplantation. In the context of un-
related cord blood transplantation (UCBT), high rate of graft fail-
ure with using ivBU + Flu regimen has been reported, thus the
optimal use of the regimen has not been established. In order to
address this issue, we retrospectively reviewed patients who under-
went UCBT with ivBU + Flu-based conditioning regimens. 49 pa-
tients, who were at ECOG performance status of 2 or less and
received UCBT at our institute from February 2007 to August
2009 consecutively, were included in this study. Median age was
59 years (range, 21-72). 42 were AML/MDS, 5 were ALL, 1
was ATL, and 1 was CML. 44 patients (89.7%) were not in remis-sion, and 13 had history of prior transplantation. Fludarabine 125-
180 mg/m2 and ivBu 6.4-12.8 mg/kg were used in all patients. All
patients received additional melphalan (Mel) or total body irradi-
ation (TBI); Mel 80-140 mg/m2 for 18 and 2-8 Gy of TBI for 31.
Graft-versus- host disease prophylaxis consisted of tacrolimus plus
mycophenolate mofetil in 39 and tacrolimus alone in 10. Single
cord blood units, matched at 4/6 in 42 and 5/6 in 7, of 2 
107/kg of recipient body weight at minimum were infused.
Thirty-seven achieved neutrophil recovery on median-day 21
(range, 13-52) post-transplant. Among 12 who failed to achieve
neutrophil recovery, 5 experienced early disease progression, 4
showed rejection, and 3 died before engraftment due to infections.
All 37 patients who achieved neutrophil engraftment showed com-
plete donor-type chimerism on median-day 14 (range, 8-35) post-
transplant. Median follow-up time of survivors was 375 days
(range, 43-958) post-transplant. Cumulative incidence of non-re-
lapse mortality (NRM) at day 100 and day 365 post-transplant
were 16.4% and 26.9%, respectively. No VOD/SOS was ob-
served. Overall survival (OS) and disease-free survival (DFS)
were 52.2% and 39.5% at 1 year, and 30.7% and 23.7% at 2years,
respectively. The results suggest that, by adding Mel or TBI, iv-
BU + Flu regimen has potential to achieve successful engraftment
of unrelated cord blood graft as well as sufficient disease control
while reducing early NRM. The optimal dosing schedule or com-
bination with other therapeutic modalities needs further investiga-
tion in prospective clinical trials.155
SIMILAR OUTCOMES IN ADULTS AND CHILDREN UNDERGOING FAMILY
HLA-MISMATCHED/HAPLOIDENTICAL HEMATOPOIETIC CELL TRANS-
PLANTATION (HCT)
Dong, L.1, Wu, T.2, Gao, Z.1, Zhang, M.-J.3, Kan, F.4, Spellman, S.R.4,
Zhao, Y.-L.2, Wang, J.-B.2, Tan, X.-Z.1, Lu, D.-P.2, Miklos, D.5,
Petersdorf, E.6, Fernandez-Vina, M.7, Lee, S.J.6 1Dao-Pei Hospital,
Shanghai, China; 2Dao-Pei Hospital, Beijing, China; 3CIBMTR, Mil-
waukee, WI; 4National Marrow Donor Program, Minneapolis, MN;
5Stanford University, Stanford, CA; 6Fred Hutchinson cancer Research
Center, Seattle, WA; 7M.D. Anderson Cancer Center, Houston, TX
Objective: Haploidentical HCT can achieve nearly comparable
therapeutic effects with HLA matched sibling HCT and may induce
more potent graft-versus-tumor effects. We tested whether the out-
comes for adults and children were different in haploidentical HCT
and sought predictors of HCT success.
Patients: Patients (pts) aged 1-65 yrs receiving myeloablative condi-
tioning regimens with 2 to 3 antigen HLA-mismatched family mem-
ber donors between 2000 and 2005 were included. 137 pts (50
children and 87 adults) were reported to CIBMTR and 181 pts (68
children and 113 adults) were from Dao-Pei Hospital in China.
The CIBMTR cohort was 53% AML, 31% ALL, 9% CML, and
7% MDS, with 26% early, 24% intermediate and 50% advanced dis-
ease. More than 80% of adults and children received either ATG or
in vitro T cell depletion (TCD). Median FU of survivors was 40
months for children and 38 months for adults. In the Chinese cohort
there were 31% AML, 35% ALL, 28% CML, and 6% MDS with
48% early, 27% intermediate and 25% with advanced disease. All
pts received ATG before HCT. Median FU of survivors was 49
months for children and 47 months for adults.
Results: In univariate analyses, 3 year survival in children and adults
was 19 (95% CI [8-32])% and 24 [15-35]% in the CIBMTR cohort,
p5NS and 54 [43-66]% and 53 [44-62]% in the Chinese cohort,
p5NS, respectively. CIBMTR and Chinese data were analyzed sep-
arately because of differences in outcomes and pt and HCT charac-
teristics. In the CIBMTR cohort, four subgroups were compared
(Adult-No TCD; Child-No TCD; Adult-TCD, Child-TCD) due
to a significant interaction between age and TCD. With TCD,
adults had a higher mortality rate than children (RR 1.75, [1.08-
2.84], p5 0.023). However, that age effect was not observed in pts
without TCD. Disease stage was also predictive of survival
(p\0.001). In the Chinese cohort, Karnofsky score$90 was associ-
ated with better survival (RR 0.35, [0.22-0.54], p\0.001) as well as
lower TRM, lower relapse and higher DFS. No significant
